Skip to content

Effect of ondansetron on pruritus in hemodialysis patients

Comparison the effect of ondansetron and placebo on pruritus in hemodialysis patients

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
IRCT
Registry ID
IRCT201111288241N1
Enrollment
70
Registered
2013-02-21
Start date
2010-09-23
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic renal failure. Renal failure

Interventions

Intervention 1: Ondansetron tablets 8 mg three times daily for two weeks in the intervention group. Intervention 2: Loratadine tablets 10 mg twice daily in the control group.
Treatment - Drugs
Placebo
Ondansetron tablets 8 mg three times daily for two weeks in the intervention group
Loratadine tablets 10 mg twice daily in the control group

Sponsors

Vice chancellor for research and education
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with chronic renal failure undergoing hemodialysis; willingness of patients for entry into the study; minimum age 18 years. Exclusion criteria: Patients with a history of skin or metabolic disease causing itching; Patients who received anti-pruritic medications two weeks before; pregnant women; People under age 18; non-cooperation Patients.

Exclusion criteria

Exclusion criteria:

Design outcomes

Secondary

MeasureTime frame
Side effect. Timepoint: During the intervention. Method of measurement: Visual and laboratory.

Primary

MeasureTime frame
Pruritus. Timepoint: Baseline - A week later, two weeks after the intervention. Method of measurement: VAS.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Mina Mirnezami

Arak University of Medical Sciences

mirnezamim@yahoo.com+98 86 1224 1411

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026